Quick facts
- Class
- Modified IGF-1 analog
- Primary legitimate use
- Cell-culture research reagent
- Studied for
- Cell growth/proliferation (in vitro)
- Approval
- Not for human use; banned by WADA
- Class
- Synthetic IGF-1 analog (peptide/growth factor)
- Approval
- None for human use; sold as research/lab reagent only
- Administration
- Injection (in illicit use); reagent added to culture media in labs
- Anti-doping
- Prohibited at all times under WADA (peptide hormones / growth factors)
Key takeaways
- Long R3 IGF-1 is a synthetic analog of insulin-like growth factor 1, modified to resist binding proteins so it stays active far longer than natural IGF-1.
- It is sold and labeled strictly as a cell-culture reagent for laboratory research, not as a medicine for human use.
- It is used illicitly in bodybuilding for claimed muscle and recovery effects, but there are no controlled human trials supporting safety or efficacy for that purpose.
- Because IGF-1 signaling promotes cell proliferation, chronic elevation raises theoretical cancer and growth-related risks; it can also cause hypoglycemia.
- It is a prohibited substance in sport under the WADA growth-factor category.
Overview
IGF-1 LR3, sometimes written Long R3 IGF-1, is a modified, long-acting analog of insulin-like growth factor 1. IGF-1 is a natural hormone that mediates many of the growth-promoting effects of growth hormone, and this engineered version is altered to remain active in the body for a longer period than the natural molecule.
It is produced and sold primarily as a laboratory reagent for use in cell-culture research, where IGF-1 analogs are valuable tools for studying cell growth and signaling. Despite this intended research role, it is also used illicitly in bodybuilding and performance settings in pursuit of muscle growth, a use unsupported by approval and accompanied by serious risks.
An honest account stresses that IGF-1 LR3 is not a medicine. It is a potent biologically active compound intended for the laboratory, and its non-research use raises significant safety and legal concerns that should not be understated.
How it works
IGF-1 LR3 binds to and activates the IGF-1 receptor, triggering signaling pathways that promote cell growth, proliferation, and survival. In muscle and other tissues, IGF-1 signaling is associated with anabolic, or growth-promoting, effects, which is the basis for its illicit appeal in performance contexts.
The molecule is modified in two key ways relative to natural IGF-1. The Long R3 modifications extend its half-life and reduce its binding to the IGF-binding proteins that normally regulate and restrain IGF-1 activity in circulation. The practical consequence is that IGF-1 LR3 remains active longer and is less subject to the body's natural buffering.
This combination of potency and reduced regulation is precisely what makes the compound concerning. Because IGF-1 signaling affects glucose metabolism and broad cell-growth pathways, a long-acting, less-restrained analog can produce powerful systemic effects, including impacts on blood sugar and on the proliferation of cells throughout the body.
Research & evidence
IGF-1 LR3 is widely used in legitimate laboratory research as a reagent to stimulate IGF-1 signaling in cultured cells, and in that controlled setting its biological activity is well documented. This research role, however, is entirely distinct from any validated human therapeutic use.
There is no body of rigorous clinical trial evidence establishing IGF-1 LR3 as a safe or effective treatment or enhancement agent in humans. Its use for muscle growth rests on the known anabolic biology of IGF-1 signaling and anecdotal reports rather than on controlled human studies demonstrating a favorable risk-benefit balance.
Importantly, the scientific literature on IGF-1 biology raises serious caution. Because IGF-1 signaling promotes cell proliferation, sustained elevation through a potent analog is theoretically linked to concerns about abnormal tissue growth, making non-medical use a matter of genuine risk rather than established benefit.
Safety & legal status
IGF-1 LR3 carries notable safety risks. Its insulin-like activity can cause hypoglycemia, or dangerously low blood sugar, which can be serious. More broadly, because IGF-1 stimulates cell growth and proliferation, chronic exposure to a potent, long-acting analog raises theoretical concerns about promoting the growth of abnormal cells, including cancer-related worries that feature prominently in discussions of IGF-1 biology. This guide provides no dosing information.
It is sold as a research reagent, typically labeled not for human use, and obtained from suppliers that do not meet pharmaceutical standards, introducing additional hazards from variable purity and sterility.
IGF-1 LR3 is not an approved drug for human use, and using it outside research falls outside any regulatory approval. It is also prohibited in sport under World Anti-Doping Agency rules. Given the combination of hypoglycemia risk, growth-signaling concerns, and unregulated sourcing, non-research use is strongly discouraged.
Frequently asked questions
Is IGF-1 LR3 an approved drug?
No. It has no regulatory approval for human use and is marketed only as a laboratory cell-culture reagent. Recombinant IGF-1 (mecasermin) is a separate, approved drug, but that is not the same product as IGF-1 LR3.
Why is it 'long-acting' compared to normal IGF-1?
It carries amino-acid substitutions and an extra peptide extension that reduce binding to IGF-binding proteins. As a result more of it remains free and biologically active, extending its effective duration.
What are the main safety concerns?
Because IGF-1 drives cell growth and division, sustained high levels raise theoretical concerns about tumor promotion and tissue overgrowth. It can also lower blood sugar, and as an unregulated research product its purity and dosing are unverified.
Is it banned in sports?
Yes. IGF-1 and its analogs fall under WADA's prohibited peptide-hormone and growth-factor classes and are banned in and out of competition.
Is there human evidence it builds muscle?
No controlled human clinical trials demonstrate that IGF-1 LR3 safely builds muscle. Claims are based on cell and animal data plus anecdote, not validated human outcomes.
References
Each source links to its original record — peer-reviewed studies, regulator pages, or reference texts, labelled by type. We summarize findings neutrally; a citation is a reference, not an endorsement, and not a claim that its authors reviewed this page.
- Voorhamme D, Yandell CA. LONG R3IGF-I as a more potent alternative to insulin in serum-free culture of HEK293 cells. Mol Biotechnol. 2006. Peer-reviewed study
- Mongongu C, Coudore F, Domergue V, et al. Detection of LongR3-IGF-I and related analogs for antidoping purposes. Drug Test Anal. 2021. Peer-reviewed study
- Renehan AG, Zwahlen M, Minder C, et al. IGF-I, IGFBP-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004. Peer-reviewed study
- Lu Z, Liu N, Huang H, et al. Recombinant expression of IGF-1 and LR3 IGF-1 fused with xylanase in Pichia pastoris. Appl Microbiol Biotechnol. 2023. Peer-reviewed study
- Hadsell DL, Parlow AF, Torres D, et al. Enhancement of maternal lactation performance during prolonged lactation in the mouse by mouse GH and long-R3-IGF-I is linked to changes in mammary signaling and gene expression. J Endocrinol. 2008. Peer-reviewed study
- Engel MG, Narayan S, Cui MH, et al. Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice. J Alzheimers Dis. 2025. Peer-reviewed study